cyrilzakka/clinical-trials huggingface dataset:
Central Venous Pressure (CVP) Assessment by Ultrasound and Physical Examination

Ultrasound may be useful for noninvasively determining the central venous pressure. We intend to compare the clinical examination of the neck veins; ultrasound delineation of the internal jugular vein; and the central venous pressure measured with an intravascular catheter.


Eligibility Criteria:
Inclusion Criteria:

* adult medical or surgical ICU patients who have preexisting central venous (jugular/subclavian only) catheters.

Exclusion Criteria:

* subjects with only a femoral venous catheter.
* subjects whose CVP measurement by the indwelling catheter exceeds 20cm of water.
* subjects younger than 18 years old.
* inability to obtain informed consent from the subject or the subjects authorized representative.
A Randomized-controlled Trial of Social Norm Interventions to Increase Physical Activity

Objective: Physical activity confers numerous health benefits, yet few adults meet recommended physical activity guidelines. The impact of brief messages providing feedback on physical activity was tested in this study. Methods: Young adults were randomly assigned to one of three conditions: (1) feedback on how active others were, (2) feedback on how active others were plus a message of approval or disapproval depending on whether the participant was more or less active than average, or (3) no feedback (control condition). Participants used pedometers for eight weekdays and recorded their step counts each evening. The group receiving feedback on how active others were got information about the average number of steps taken by group members the previous day. The group that also received approval or disapproval received feedback about the group average, as well as a sad face if the participant was below the average or a happy face if the participant was above the average. The control group received no feedback throughout the study. Impacts of these feedback messages were compared on number of steps taken during the study.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 or older

Exclusion Criteria:

* Answering yes to any questions on the Physical Activity Readiness Questionnaire.
Photobiomodulation Therapy on Low Back Pain

Photobiomodulation therapy (PBMT) is a non-pharmacological method commonly used in treatment of musculoskeletal disorders. However, there are few high-quality scientific evidence to support the effectiveness of this therapy in the treatment of patients with chronic low back pain, at short, medium and long term. The present research project aims to evaluate the effects of PBMT in patients with chronic non-specific low back pain.

This is a randomized, triple-blinded, placebo-controlled trial, with voluntary patients with chronic non-specific low back pain.One hundred and forty-eight patients will be randomly allocated to two treatment groups: Placebo or PBMT for 4 weeks (3 times per week, total of 12 sessions of 27 minutes each). The clinical outcomes will be obtained at the completion of treatment (4 weeks) and at 3, 6 and 12 months after randomization. The data will be collected by a blinded assessor. The statistical analysis will follow the intention-to-treat principles and the between-group differences will be calculated by using mixed linear models.

The outcomes of interest are pain intensity, disability, function and global perceived effect.

Eligibility Criteria:
Inclusion Criteria:

* patients seeking care for chronic non-specific low back pain (defined as pain or discomfort between the costal margins and the inferior gluteal folds, with or without referred symptoms in the lower limbs, for at least 3 month);
* with a pain intensity of at least 3 points measured by a 0-10 points pain numerical rating scale;
* aged between 18 and 65 years;
* able to read Portuguese.

Exclusion Criteria:

* evidence of nerve root compromise (i.e. one or more of motor, reflex or sensation deficit);
* serious spinal pathology (such as fracture, tumor, inflammatory and infectious diseases);
* serious cardiovascular and metabolic diseases;
* previous back surgery;
* pregnancy.
Whitening Efficacy and Tooth Sensitivity of Different Concentrations of Hydrogen Peroxide Photoactivated With Violet or Blue LEDs

This is a randomized, controlled, double-blind and repeated-measures clinical trial evaluated the photoactivation of hydrogen peroxide gels in different concentrations with blue or violet LED in terms of whitening efficacy and tooth sensitivity.


Eligibility Criteria:
Inclusion Criteria:

* at age 18 or older, with good general and oral health;
* possessing all six natural and healthy upper anterior teeth with a color shade of A2 or darker, determined by comparison with the Vita Classic scale;

Exclusion Criteria:

* pregnant and breastfeeding women;
* individuals with internal tooth discoloration (tetracycline stains, fluorosis or hypoplasias);
* smokers, or those with veneers or restorations on the teeth in questions were excluded;
* gingival recession;
* dentin exposure;
* periodontal disease.
Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children

In Sickle cell disease children, sleep respiratory abnormalities are risk factors for vaso-occlusive complications, as well as cerebral vasculopathy.

A 18 months follow-up children with sickle cell disease evaluating sleep respiratory problems frequency and etiology, as well as their influence on sickle cell disease complications.

* Inclusion visit with physical examination. A 2.9 ml blood sample will be necessary, if not done within the framework of care within 6 months for: CBC (Cell Blood Count), reticulocytes counts (1.2 ml of blood), liver enzymes, electrolytes, urea, creatininemia (1,2 ml of blood) and fetal hemoglobin (0.5 ml of blood). - A complete standardized examination including nasopharynx endoscopy, if not yet done in usual care, to identified upper airway obstruction
* A standardized pneumology evaluation to identified obstructive lung symptomatology
* An ambulatory polysomnography will be performed within days following inclusion, during sleep and will allow electroencephalogram recording, oculomotricity, muscles (mentalis muscles and tibialis anterior) movements, electrocardiogram and respiratory activity recording.

The steering committee will classify the children in three populations based on their exam results:

* Group 1: no abnormality in polysomnography
* Group 2: obstructive sleep-related disorder
* Group 3: isolated sleep hypoxemia for group3, patients will have a new ambulatory polysomnography.

Eligibility Criteria:
Inclusion Criteria:

* Sickle cell disease children with either sickle cell anemia, compound heterozygozity SB0-thalassemia, or SDPunjab,
* no prior transfusion program within 3 months,
* no prior treatment with hydroxycarbamide within 3 months,
* Aged 2 to 6 years,
* Parents or tutors signed informed consent,
* Prior physical examination,
* Social security insurance.

Exclusion criteria:

* Encephalopathy
* Other disease that could interfere with protocol exams realization
* Nitrous oxide analgesia contre-indication
* Conventional hospitalization in the past 3 weeks
Biomechanical Assessment of Level Gait in Patient's Status Post Bladder Exstrophy

The purpose of this study is to determine whether patients who have undergone exstrophy closure may be at risk for long-term orthopedic issues manifest by gait abnormalities. This study is a descriptive analysis of the study cohort's gait patterns and pelvic structure.

Specific Aim 1: to determine whether patients with classic bladder exstrophy who underwent closure demonstrate gait abnormalities.

Hypothesis 1: Patients undergoing closure of bladder exstrophy (with or without pelvic osteotomy) demonstrate gait abnormalities compared with a reference population.

Hypothesis 2: Patients undergoing closure of bladder exstrophy (with or without pelvic osteotomy) will have below normal functional survey scores.


Eligibility Criteria:
Inclusion Criteria:

1. Subject was seen at CCMC for bladder exstrophy between January 2002 and December 2010.
2. Subject is four years of age or older at time of enrollment.
3. Subject has the ability to walk.
4. Subject has not had gait testing performed.
5. Subject provides Informed Consent and HIPAA Authorization.

Exclusion Criteria:

1. Subject was not seen at CCMC for bladder exstrophy between January 2002 and December 2010.
2. Subject under four years of age at time of enrollment.
3. Subject does not have the ability to walk.
4. Subject had prior gait testing performed.
5. Subject not willing to provide Informed Consent and HIPAA Authorization.
Lymphocyte Profiles and Activation Status in Patients With Graft-Versus-Host Disease

This research trial studies lymphocyte profiles and activation status in patients with graft-versus-host disease. Studying samples of blood in the laboratory from patients with cancer may help doctors identify and learn more about biomarkers related to graft-versus-host disease.

PRIMARY OBJECTIVES:

I. To explore and assess changes in subsets and activation status of B-, T,-, and natural killer (NK) lymphocytes in peripheral blood following allogeneic stem cell transplant and how they may be associated with clinical events with an ultimate future goal of conducting a larger successor study to identify potential therapeutic targets based on its findings.

SECONDARY OBJECTIVES:

I. To assess the feasibility of obtaining and comparing patients with chronic graft-versus-host disease (cGVHD) with time-matched stem cell transplant (SCT) patients without cGVHD and identify logistical challenges with obtaining and processing samples in each of the subgroups of interest for these analyses.

II. To assess and explore differences in lymphocyte subsets (B-, T-, and NK) between those with vs. without cGVHD.

III. To assess and explore differences in cytokines in patients with cGVHD vs. those without.

IV. To describe lymphocyte subsets and activation and explore how these may be related to specific clinical manifestations of cGVHD.

OUTLINE:

Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunosorbent spot (ELISPOT), immunoblot, and microarray assays.

Eligibility Criteria:
Inclusion Criteria:

* Allogeneic SCT groups: Patients who have received stem cell transplantation at The Ohio State University are eligible and who are at or beyond day +75 following allogeneic SCT regardless of previous diagnosis of acute or chronic graft-versus-host disease (GVHD)
* Autologous SCT group: Patients who have received an autologous stem cell transplant at The Ohio State University and who have achieved platelet and neutrophil engraftment
Short-Term Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions

An investigational multi-purpose solution (MPS)was clinically evaluated against Biotrue MPS at specific time points over the course of four days. The study was conducted with PureVision lenses.


Eligibility Criteria:
Inclusion Criteria:

* were at least 18 years old;
* were experienced contact lens wearers;
* were correctable to at least 20/40 or better in both eyes with contact lenses;
* were in good general health, with healthy eyes (other than requiring vision correction);
* had not worn lenses for at least 12 hours before each baseline visit;
* had a corneal staining score no greater than Grade 1 in either eye at time of enrollment;
* had previously used an MPS or hydrogen peroxide solution successfully.

Exclusion Criteria:

* had a confirmed diagnosis of Sjögren's syndrome or other condition that results in a chronic and/or pathologic dry eye condition;
* required concurrent ocular medication or have used ocular medication within 24 hours of entering the study;
* had a known sensitivity or intolerance to any MPS, study products or ingredient(s);
* were currently participating in any other clinical study;
* had a condition or are in a situation that, in the investigator's opinion, may put them at significant risk, confound the study results, or interfere significantly with their participation in the study.
Testing the Cog-Fun Aging Program for Older Adults with Subjective Cognitive Decline

The goal of this clinical trial is to learn if the Cog-Fun Aging program helps older adults with Subjective Cognitive Decline (SCD) manage memory challenges and improve their daily lives. The main questions it aims to answer are:

* Does the program help participants better understand their cognitive challenges in daily life?
* Do participants report using more effective strategies to manage their memory difficulties?
* Does the Cog-Fun Aging program reduce negative emotions and self-perceptions related to SCD?

Researchers will compare participants who complete the Cog-Fun Aging program with those who do not to determine the program's effectiveness.

Participants will:

Take part in a 10-week program with weekly sessions. Learn about SCD and how it affects daily life. Practice and monitor strategies to manage memory difficulties.


Eligibility Criteria:
Inclusion Criteria:

* experiencing memory changes and feeling concerned about them
* a score of 23 or higher on the MoCA (Montreal Cognitive Assessment)
* ability to speak and understand Hebrew sufficiently to participate in a Hebrew-speaking group

Exclusion Criteria:

* a self-reported health condition that significantly impacts functioning (e.g., uncontrolled diabetes, severe heart/lung disease)
* residing in a medical institution or nursing home
* currently participating in another SCD treatment
Advance Care Planning Notifications in General Inpatient Medicine

This study will evaluate the impact of and response by physicians on Hospital Medicine/General Internal Medicine service to a notification identifying seriously ill patients at high risk of death within 30 days as well as within 6 months in a cluster randomized control trial.


Eligibility Criteria:
Inclusion Criteria:

* At least 18 years of age
* Attending Physician on the Hospital Medicine or General Internal Medicine Service at Duke University Hospital

Exclusion Criteria:

* None
Antecedents of Obesity: Fetal Measures of Adiposity

The purpose of this research is to study whether fetal biometrics obtained by 2-D ultrasound can predict infant adiposity by air displacement plethysmography at birth.


Eligibility Criteria:
Inclusion Criteria:

* Infants of mothers between the ages of 18 and 45, planning child birth at the University of Utah Hospital, and willing to provide parental permission for the child to participate in the study.

Exclusion Criteria:

* Infants of mothers under the age of 18, over the age of 45, planning child birth at another facility other than the University of Utah Hospital, or who are not willing to provide permission for the child to participate in the study.
Physical Abilities of Teenagers With Familial Mediterranean Fever

Physical abilities of teenagers with familial Mediterranean fever

Physical abilities of teenagers with familial Mediterranean fever by describing the maximum oxygen consumption (VO2max) estimated from a 6-minute walk test

Eligibility Criteria:
Inclusion Criteria:

* Patients with a clinical diagnosis of FMF according to the Tel-Hashomer criteria for whom a sports evaluation was offered during their bridging program
* Age \>12
* Followed or having been followed in the pediatric department of the CH of Versailles
* No opposition of the patient and his/her parent/legal guardian in case of a minor patient

Exclusion Criteria:

Expressed refusal of the patient and his/her parent/legal guardian to participate in the study and/or to use genetic data for research purposes
Defining the Serum Ferritin Concentration in Kenyan Women at Which the Body Senses Iron Depletion and Begins to Upregulate Iron Absorption

The serum or plasma ferritin concentration (referred to hereafter as ferritin) is the most widely used indicator to detect iron deficiency and a low ferritin indicates depleted iron stores. However, the threshold ferritin that defines iron deficiency remains unclear and diagnostic ferritin cutoffs from expert groups vary widely.

Our study aim is to define the ferritin in Kenyan young women at which the body senses iron depletion and begins to upregulate iron absorption from the diet; this approach could provide a functionally defined threshold of iron deficiency in Sub-Saharan African women.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-28 y, not pregnant or lactating
* Body weight \<75 kg
* body mass index (BMI) between 17 and 25 kg/m2
* No acute illness/infection (self-reported)
* No metabolic or gastrointestinal disorders (self-reported)
* No use of medications affecting iron absorption or metabolism during the study
* No intake of mineral/vitamin supplements 2 weeks prior to the first study visit and during the study
Lactoferrin Versus Ferrous Sulphate for the Treatment of Iron Deficiency Anemia During Pregnancy

The study aims to compare the efficacy and the safety of Lactoferrin versus ferrous sulphate for the treatment of iron deficiency anemia during pregnancy.

The study was done at ainshams university maternity hospital on 100 pregnant women randomized in two groups .

Group one lactoferrin group Group two ferrous sulphate group

Eligibility Criteria:
Inclusion Criteria:

* pregnant women from 20 to 40 years
* iron deficiency anemia (mild and moderate)
* gestational age 13 to 26 weeks
* singleton viable pregnancy.

Exclusion Criteria:

* history of anemia due to chronic blood loss
* hemolytic anemia
* severe anemia
* history of peptic ulcer
The Effect of Oral Carbohydrate Inhalation Given to Patients Before Coronary Artery Bypass Graft Operation on Recovery

The aim of this study was to investigate the effect of oral carbohydrate solution given to patients before coronary artery bypass graft surgery on nausea-vomiting, hunger, thirst, physiologic parameters and recovery.

The study will be completed with a total of 120 participants, 40 control, 40 placebo and 40 experimental.

As a randomization method, simple randomization method will be used to provide an equal number of samples in three groups and patients will be informed verbally about the study and written informed consent will be obtained from patients who agree.

In this study, the effects of oral carbohydrate solution administration on nausea and vomiting, hunger, thirst, physiologic parameters and recovery were evaluated before coronary artery bypass graft surgery.

Experimental: Oral administration of carbohydrate solution Patients will receive 800 ml of oral carbohydrate solution until midnight before surgery and 400 ml until 2 hours before surgery. Patients will be administered a Patient Information Form before surgery. Postoperative Recovery Index (Turkish Version), Visual Comparison Scale, Physiologic Parameters and Blood Glucose Monitoring Form and Number and Dosage of Antiemetic Drugs Taken in 24 Hours Postoperatively will be applied.

Placebo: Administration of flavored water Patients will be given 800 ml of flavored water until midnight before surgery and 400 ml of flavored water until 2 hours before surgery. Patients will be given a Patient Information Form before surgery. Postoperative Recovery Index (Turkish Version), Visual Comparison Scale, Physiologic Parameters and Blood Glucose Monitoring Form and Number and Dosage of Antiemetic Drugs Taken in 24 Hours Postoperatively will be applied.

Control: No intervention Patients will be administered a Patient Information Form before surgery. Postoperative Recovery Index (Turkish Version), Visual Comparison Scale, Physiologic Parameters and Blood Glucose Monitoring Form and Number and Dosage of Antiemetic Drugs Taken in 24 Hours Postoperatively will be applied.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Planned coronary artery bypass graft surgery
* Volunteering to participate in the research

Exclusion Criteria:

* Under 18 years of age
* Not planned coronary artery bypass graft surgery
* Not volunteering to participate in the research
* Cases received as an emergency
Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan

This clinical lactation study is to provide information regarding the PK and amount of OLZ/SAM in breast milk and estimated infant exposure.


Eligibility Criteria:
Inclusion Criteria:

* Body mass index ≥18 and \<35 kg/m2
* Subject is lactating, at least 4 weeks post-partum at dosing, and is using or willing to use an electronic breast pump for sample collection
* Subject is willing to temporarily discontinue breastfeeding for the duration of at least 11 days post-dose
* Subject is exclusively breastfeeding and/or pumping milk, or if not exclusively breastfeeding/pumping, has an adequate milk supply as judged by the Investigator
* Subject's infant is able to bottle-feed
* Subject agrees to use contraception during the study

Exclusion Criteria:

* Subject has a history of lumpectomy, mastectomy, breast implants, breast augmentation, or breast reduction surgery
* Breastfeeding is not well-established or milk supply is low as judged by the Investigator
* Subject has mastitis or other condition that may prevent the collection of milk from one or both breasts
* Subject is pregnant or plans to become pregnant during the study
* Subject has had a clinically significant illness within 30 days or has had a serious infection (eg, pneumonia or septicemia) within the 3 months
* Subject has had any vaccination within 2 weeks prior to Screening or plans to have any vaccination during the study
* Subject has a history of known or suspected intolerance, allergy, or hypersensitivity to olanzapine or opioid antagonists, , or any component of the study drug (eg naltrexone, naloxone)
* Subject has a history of cardiovascular disease, cerebrovascular disease, a seizure disorder, personal or family history of neuroleptic malignant syndrome, or known risk of narrow-angle glaucoma or orthostatic hypotension
* Subject has a current or anticipated need for prescribed opioid medication during the study period
* Subject has a positive urine drug screen for amphetamine, barbiturates, cannabinoids, cocaine, or opioids or positive cotinine test
Safety of Closed-loop Hybrid Insulin Administration During Ramadan Fasting in People Living With Type 1 Diabetes

Fasting in Ramadan is not recommended for people with type 1 diabetes. The main risk associated with fasting is dysglycemia (hypoglycemia, hyperglycemia, diabetic ketosis) and dehydration. Nevertheless, whether or not to practice Ramadan remains a personal choice and many people living with diabetes choose to perform this fast with or without their physician's approval. The purpose of this prospective observational study is to evaluate the safety and efficacy of an closed-loop hybrid insulin system on glycemic parameters and the level of hypoglycemia in patients with type 1 diabetes who wished to fast during Ramadan.

Primary objective: to evaluate the efficacy of an closed-loop hybrid insulin system on continuous glucose monitoring (CGM) glycemic parameters during the Ramadan fasting period Primary endpoint : to compare the time spent in the 3.9-10.0 mmol/l glucose target (TIR) from 30 days prior to the Ramadan fasting period to 30 days during the fasting period

Eligibility Criteria:
Inclusion Criteria:

* age \> 18 years
* type 1 diabetes for \> 1 year
* on using closed-loop hybrid insulin administration
* scheduled Ramadan fasting
* patient put on using closed-loop hybrid insulin administration more than 2 months before the start of the Ramadan fast
* percentage of continuous glucose monitoring sensor wear \> 70% in at least one of the two 30-day periods

Exclusion Criteria:

* patient put on using closed-loop hybrid insulin administration less than 2 months before the start of the Ramadan fast
* patient who is pregnant or wants to become pregnant immediately
* patient informed of the study who objected to the collection of his/her data.